Cobicistat
Cytochrome P450 3A Inhibitor — ANTIINFECTIVES FOR SYSTEMIC USE
Also known as: GS 9350, GS-9350, tybost
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Cobicistat is an onp drug in the Cytochrome P450 3A Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2012. Its mechanism of action is classified as Breast Cancer Resistance Protein Inhibitors, Cytochrome P450 2D6 Inhibitors and Cytochrome P450 3A Inhibitors. DrugCentral lists 3 molecular targets, including CYP3A4|CYP3A5|CYP3A7|CYP3A43, REP and ABCG2. Recorded indications include Human immunodeficiency virus infection and Malignant Melanoma with BRAF V600E Mutation.
- Approval status: onp (first approved 2012 by the FDA).
- Drug class: Cytochrome P450 3A Inhibitor.
- Mechanism of action: Breast Cancer Resistance Protein Inhibitors; Cytochrome P450 2D6 Inhibitors; Cytochrome P450 3A Inhibitors.
- Molecular targets: CYP3A4|CYP3A5|CYP3A7|CYP3A43, REP and ABCG2 (3 listed in DrugCentral).
- Indications: Human immunodeficiency virus infection and Malignant Melanoma with BRAF V600E Mutation.
- ATC code: J05AR09 (Antivirals for treatment of HIV infections, combinations).
- Molecular formula: C40H53N7O5S2; molecular weight 776.03 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Human immunodeficiency virus infection
- Malignant Melanoma with BRAF V600E Mutation
Off-label uses (1)
- Coronavirus infection
Mechanism & targets
| Mechanism of action (MoA) | Breast Cancer Resistance Protein Inhibitors; Cytochrome P450 2D6 Inhibitors; Cytochrome P450 3A Inhibitors; Multidrug and Toxin Extrusion Transporter 1 Inhibitors; Organic Anion Transporting Polypeptide 1B1 Inhibitors; Organic Anion Transporting Polypeptide 1B3 Inhibitors; P-Glycoprotein Inhibitors |
|---|---|
| Established pharmacologic class | Cytochrome P450 3A Inhibitor |
Molecular targets (3)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Cytochrome P450 3A | CYP3A4|CYP3A5|CYP3A7|CYP3A43 | inhibitor | Ki 6.03 |
| Replicase polyprotein 1ab | REP | unknown | Kd 5.66 |
| ATP-binding cassette sub-family G member 2 | ABCG2 | unknown | IC50 4.23 |
Regulatory approvals (3)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2013-09-19 | EMA | — | Gilead Sciences Ireland UC | |
| 2013-03-25 | PMDA | — | Japan Tobacco Inc. | Yes |
| 2012-08-27 | FDA | — | GILEAD SCIENCES INC |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
J05AR09 | ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HIV infections, combinations |
J05AR14 | ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HIV infections, combinations |
J05AR15 | ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HIV infections, combinations |
J05AR18 | ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HIV infections, combinations |
J05AR22 | ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HIV infections, combinations |
V03AX03 | VARIOUS › ALL OTHER THERAPEUTIC PRODUCTS › ALL OTHER THERAPEUTIC PRODUCTS › Other therapeutic products |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Drug interaction | 418.3 |
| Immune reconstitution inflammatory syndrome | 152.0 |
| Foetal growth abnormality | 103.4 |
| Serotonin syndrome | 101.3 |
| Virologic failure | 98.2 |
| Foetal exposure during pregnancy | 94.0 |
| Adrenal insufficiency | 93.6 |
| Gastroschisis | 84.6 |
| Renal dysplasia | 71.4 |
| Congenital intestinal malformation | 70.2 |
| Single functional kidney | 67.6 |
| Viral load increased | 57.4 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Cobicistat is on its molecule page.
| Molecular formula | C40H53N7O5S2 |
|---|---|
| Molecular weight | 776.03 g/mol |
| CAS number | 1004316-88-4 |
| InChIKey | ZCIGNRJZKPOIKD-CQXVEOKZSA-N |
| PubChem CID | 25151504 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Cobicistat used for?
DrugCentral lists the following indications for Cobicistat: Human immunodeficiency virus infection and Malignant Melanoma with BRAF V600E Mutation.
How does Cobicistat work?
Cobicistat is classified as Breast Cancer Resistance Protein Inhibitors, Cytochrome P450 2D6 Inhibitors and Cytochrome P450 3A Inhibitors; its molecular targets in DrugCentral include CYP3A4|CYP3A5|CYP3A7|CYP3A43 (inhibitor), REP and ABCG2.
When was Cobicistat first approved?
Cobicistat was first approved by the FDA in 2012.
What drug class does Cobicistat belong to?
Cobicistat is in the Cytochrome P450 3A Inhibitor class.
What is the chemical formula of Cobicistat?
Cobicistat has the molecular formula C40H53N7O5S2 and a molecular weight of 776.03 g/mol.
Browse: all drugs starting with C · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4299 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL2095208 — compound record and bioactivity
- PubChem CID 25151504 — chemical identifiers
- DrugBank DB09065 — drug record
- FDA UNII LW2E03M5PG — substance identity
- DailyMed: FDA labels for Cobicistat — current prescribing information (label search)
- UniProt Q9UNQ0 (ABCG2) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.